Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2018-08-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB),
which CDX-011 binds to. The study will also further characterize the safety of CDX-011
treatment in this patient population.